SUCLG2-AS1

Across TCGA pan-cancer cohorts, SUCLG2-AS1 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of SUCLG2-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SUCLG2-AS1 RNA is repressed in tumor relative to normal tissue. In most cancer types SUCLG2-AS1 is over-expressed in tumor, although a few such as KIRC and COAD show the opposite, repressed pattern.

KIRC, COAD, and THCA are the cancer types where SUCLG2-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SUCLG2-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−0.951	<.001	11	view →
COAD	All	IV	−0.670	<.001	11	view →
THCA	Male	III,IV	−1.090	<.001	10	view →
LUSC	Male	All	−0.409	<.001	7	view →
LUAD	All	All	+0.302	<.001	7	view →
BRCA	Female	All	−0.288	<.001	6	view →
READ	Female	All	−0.676	<.001	5	view →
KIRP	Male	All	−0.539	.001	2	view →
STAD	Female	All	−0.394	.025	2	view →
PAAD	Female	All	−0.285	.034	2	view →
PRAD	All	All	+0.213	.013	2	view →
KICH	All	All	−0.480	.022	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

SUCLG2-AS1–KIRC

Open the KIRC breakdown →